Obesity surgery

Higher Salt Intake with a Carbohydrate Meal and Blood Sugar Control in Non-Diabetic People after Gastric Bypass Surgery

Updated

Abstract

The addition of 2 g of sodium chloride during a carbohydrate-rich meal reduced peak plasma glucose in individuals post-Roux-en-Y gastric bypass.

  • Nadir postprandial plasma glucose levels were similar with and without sodium supplementation (3.7 mmol/L vs 3.5 mmol/L).
  • Peak plasma glucose was significantly lower with sodium chloride (7.8 mmol/L) compared to without (8.3 mmol/L).
  • No differences were detected in area under the curve for glucose or in fasting and peak insulin, c-peptide, and GLP-1 concentrations.
  • The findings suggest that sodium supplementation does not substantially alter glucose homeostasis post-RYGB.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declarations. Ethical Approval: Ethical approval for the study was granted by the Yorkshire & Humber South Yorkshire Research Ethics Committee (20/YH/0177). The study was registered in the ISRCTN registry (ISRCTN12008159). All study procedures were carried out in accordance with good clinical practice guidelines and the Declaration of Helsinki (1964). Informed Consent: All participants provided written informed consent prior to being enrolled onto the study. Competing Interests: DP has acted as a speaker for Novo Nordisk, Eli Lilly, Boehringer Ingelheim and Johnson and Johnson and has received grants from Novo Nordisk, Novo Nordisk UK Research Foundation, Academy of Medical Sciences/Diabetes UK, Health Education East Midlands and the National Institute for Health and Care Research (NIHR). II has received research grant or speaker fees for: Eli Lilly, Novo Nordisk, Boehringer, Sanofi, Astra Zenica. MJD has acted as a consultant/advisor and speaker for Eli Lilly, Novo Nordisk and Sanofi, has attended advisory boards for AbbVie, Amgen, AstraZeneca, Biomea Fusion, Carmot/Roche, Sanofi, Zealand Pharma, Regeneron, GSK and EktaH and as a speaker for AstraZeneca and Boehringer Ingelheim and has received grants from AstraZeneca, Boehringer Ingelheim and Novo Nordisk.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free